An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2016
This article has no abstract
Epistemonikos ID: cfa47c45aa87f68cda7d774d247edcb1aae31501
First added on: Jan 23, 2025